The conclusion of the Expert Council 'The product rationale based on inositol for use by patients with menstrual irregularities'

The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Search result: 0

Vorontsova A.V.

N.I. Pirogov Russian National Research Medical University

Gasparyan S.A.

Stavropol State Medical University, Stavropol, Russia

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

ORCID: 0000-0002-7663-710X

Dzhobava .M.

Kafedra akusherstva i ginekologii #2 lechebnogo fakul'teta Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Kiseleva E.Yu.

Korotkikh I.N.

Кuleshov V.М.

Novosibirsk State Medical University, Novosibirsk, Russia, 630091

Oboskalova T.A.

Kafedra akusherstva i ginekologii

Pustotina O.A.

Kafedra akusherstva i ginekologiii s kursom perinatologii Rossiĭskogo universiteta druzhby narodov, Moskva

Sakhautdinova I.V.

Spiridonova N.V.

Kafedra akusherstva i ginekologii Instituta poslediplomnogo obrazovaniia GBOU VPO "Samarskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF

Tapil'skaia N.I.

Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Tkhostova E.B.

The conclusion of the Expert Council 'The product rationale based on inositol for use by patients with menstrual irregularities'

Authors:

Vorontsova A.V., Gasparyan S.A., Gromova O.A., Dzhobava .M., Kiseleva E.Yu., Korotkikh I.N., Кuleshov V.М., Oboskalova T.A., Pustotina O.A., Sakhautdinova I.V., Spiridonova N.V., Tapil'skaia N.I., Tkhostova E.B.

More about the authors

Journal: Russian Journal of Human Reproduction. 2020;26(1): 44‑54

DOI: 10.17116/repro20202601144

Views: 29457

Downloaded: 801

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Vorontsova AV, Gasparyan SA, Gromova OA, et al. . The conclusion of the Expert Council 'The product rationale based on inositol for use by patients with menstrual irregularities'. Russian Journal of Human Reproduction. 2020;26(1):44‑54. (In Russ.)
https://doi.org/10.17116/repro20202601144

Close metadata

Authors:

Vorontsova A.V.

N.I. Pirogov Russian National Research Medical University

Gasparyan S.A.

Stavropol State Medical University, Stavropol, Russia

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

ORCID: 0000-0002-7663-710X

Dzhobava .M.

Kafedra akusherstva i ginekologii #2 lechebnogo fakul'teta Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta im. N.I. Pirogova, Moskva

Kiseleva E.Yu.

Korotkikh I.N.

Кuleshov V.М.

Novosibirsk State Medical University, Novosibirsk, Russia, 630091

Oboskalova T.A.

Kafedra akusherstva i ginekologii

Pustotina O.A.

Kafedra akusherstva i ginekologiii s kursom perinatologii Rossiĭskogo universiteta druzhby narodov, Moskva

Sakhautdinova I.V.

Spiridonova N.V.

Kafedra akusherstva i ginekologii Instituta poslediplomnogo obrazovaniia GBOU VPO "Samarskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava RF

Tapil'skaia N.I.

Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Tkhostova E.B.

List of references:

Registr lekarstvennykh sredstv Rossii. M. 2002.
https://www.kp.ru/daily/24113/336580
Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007;11(5):347-354.
Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature. 2006;443(7112):651-657. https://doi.org/10.1038/nature05185
Larner J, et al. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol. Biochem Biophys Res Commun. 1988;151:1416-1426.
Lauretta R, Lanzolla G, Vici P, Mariani L, Moretti C, Appetecchia M. Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk. Int J Endocrinol. 2016;8671762. Epub 2016 Sep 20. PMID: 27725832; PMCID: PMC5048026. https://doi.org/10.1155/2016/8671762
Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811-1827. https://doi.org/10.1016/j.biochi.2013.05.011
Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002;293(3):1092-1098. https://doi.org/10.1016/S0006-291X(02)00313-3
Yap A, Nishiumi S, Yoshida K, Ashida H. Rat L6 myotubes as an in vitro model system to study GLUT4-dependent glucose uptake stimulated by inositol derivatives. Cytotechnology. 2007;55(2-3):103-108. Epub 2007 Oct 31. PMID: 19002999; PMCID: PMC2104555. https://doi.org/10.1007/s10616-007-9107-y
Dang NT, Mukai R, Yoshida K, Ashida H. D-pinitol and myo-inositol stimulate translocation of glucose transporter 4 in skeletal muscle of C57BL/6 mice. Biosci Biotechnol Biochem. 2010;74(5):1062-1067. https://doi.org/10.1271/bbb.90963
Gromova OA, Torshin IYu, Limanova OA. Perspektivy ispol'zovaniya mio-inozitola u zhenshchin s polikistozom yaichnikov i insulinorezistentnost'yu v programmakh pregravidarnoi podgotovki k ekstrakorporal'nomu oplodotvoreniyu. Effektivnaya farmakoterapiya. 2013;51:12-23.
Gulyaev AE, Nurgozhin TS, Yermekbayeva BA, Kushugulova AR, Zhaugasheva SK, Supiev AT, Kenesary AU, Nurgozhina EB. Metformin as a promising geroprotector (literature review). Russkii meditsinskii zhurnal. 2011;19(31):1986-1989. (In Russ.)
Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009;147(2):120-123.
Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361(6410):315-325.
Tesarik J, Sousa M. Mechanism of calcium oscillations in human oocytes: a two-store model. Mol Hum Reprod. 1996;2(6):383-386.
Goud PT, Goud AP, Leybaert L et al. Inositol 1, 4, 5-trisphosphate receptor function in human oocytes: calcium responses and oocyte activation related phenomena induced by photolytic release of InsP (3) are blocked by a specific antibody to the type I receptor. Mol Hum Reprod. 2002;8(10):912-918.
Cavalli P, Copp AJ. Inositol and folate resistant neural tube defects. J Med Genet. 2002;39(2):E5.
Fazleen NE, Whittaker M, Mamun A. Risk of metabolic syndrome in adolescents with polycystic ovarian syndrome: A systematic review and meta-analysis. Diabetes Metab Syndr. 2018.
Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 12:1997b2641-2648. https://doi.org/10.1093/humrep/12.12.264,
Urbanek M. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab. 2007;3:103-111. https://doi.org/10.1038/ncpendmet0400
Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55-59. https://doi.org/10.1038/ng.732
Du J, Wang J, Sun X, Xu X, Zhang F, Wang B, et al. Family-based analysis of INSR polymorphisms in Chinese PCOS. Reprod Biomed. 2014;29:239-244. https://doi.org/10.1016/j.rbmo.2014.03.028
De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016;14:38. https://doi.org/10.1186/s12958-016-0173-x
El Hayek S, Bitar L, Hamdar LH, Mirza FG, Daoud G. Poly cystic ovarian syndrome: an updated overview. Front Physiol. 2016;7:124. https://doi.org/10.3389/fphys.2016.00124
Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab. 2009;296:238-243. https://doi.org/10.1152/ajpendo.90684.2008
Liu N, Ma Y, Wang S, Zhang X, Zhang Q, Zhang X, et al. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome. Reprod Biol Endocrinol. 201210:36. https://doi.org/10.1186/1477-7827-10-36
Cadagan D, Khan R, Amer S. Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod Biol. 2016;16:53-60. https://doi.org/10.1016/j.repbio.2015.12.006
Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17:17-33. https://doi.org/10.1093/humupd/dmq032
Toprak S, Yönem A, Akir BC, Güler S, Azal O, Ozata M, et al. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res. 2001;55:65-70. https://doi.org/10.1159/000049972
Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28:969-973. https://doi.org/10.3109/09513590.2012.685205
Sutton LN. Fetal surgery for neural tube defects. Best Practice & Research Clinical Obstetrics and Gynecology. 2014;1-9.
Schmandt. Obesity and endometrial cancer risk. Am J Obstet Gynecol. 2011.
Nestler, et al. ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340:1314-1320.
Facchinetti F, Orrù B, Grandi G, Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecological Endocrinology. 2019.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Azziz R. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility. 2018;110(3):364-379. https://doi.org/10.1016/j.fertnstert.2018.05.004
Noventa M, et al. Preventive and Therapeutic Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of Evidences and Future Applications. Pennsylvania State Univ. 2016.
Scarselli F, et al. Analysis of MYO-Inositol effect on spermatozoa motility, in hyper viscous ejaculates and in patients with grades II and III varicocele. Arch Ital Urol Androl. 2016;88(4):279-283. https://doi.org/10.4081/aiua.2016.4.279
Regidor PA. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature Hormone Molecular Biology and Clinical Investigation. 2018;20170067.
Cavalli P, Copp AJ. Inositol and folate resistant neural tube defects. J Med Genet. 2002;39:e5. http://www.jmedgenet.com/cgi/content/full/39/2/e5
Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. Frontiers in Farmacology. 2017;8:341. https://doi.org/10.3389/fphar.2017.00341

Close metadata

Log in to the site using your account in one of the services

Registration

Last Name

Name

Middle Name

E-mail

Phone

Address

Country

Zip

City

Region

Street

Home

Apartmen

Legal entity name

ИНН

КПП

Password

Password

Repeat password

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.